PARIS--(BUSINESS WIRE)--Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that the Company and its partner, Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp), will initially focus their collaboration on developing point-of-care (P-O-C) diagnostics and drug delivery systems for tropical diseases, such as malaria. BiotechCorp has acquired an exclusive, global license to a Nanobiotix nanotechnology platform for non-cancer purposes. As part of the collaboration, three BiotechCorp scientists will take up residence at Nanobiotix for a period of 12 months to undergo the technology transfer training.
